Table 3.
Drug therapy and clinical outcomes during hospital stay.
| Overall (n = 674) |
CCS (n = 112) |
No-CCS (n = 562) |
p | |
|---|---|---|---|---|
| Drug therapy, n (%) | ||||
| Antibiotics | 327 (48.5) | 58 (51.8) | 269 (47.9) | 0.448 |
| Antivirals | 367 (54.4) | 56 (50) | 311 (55.3) | 0.3 |
| Steroids | 87 (12.9) | 16 (14.3) | 71 (12.6) | 0.634 |
| Hydroxychloroquine | 520 (77.1) | 86 (76.8) | 434 (77.2) | 0.92 |
| Tocilizumab | 126 (18.7) | 13 (11.6) | 113 (20.1) | 0.035 |
| Heparin | 294 (43.6) | 67 (59.8) | 227 (40.4) | <0.001 |
| Deaths, n (%) | 105(15.6) | 47 (42.0) | 58 (10.3) | <0.001 |
| Intensive care unit admission, n (%) | 46 (6.8) | 6 (5.4) | 40 (7.1) | 0.5 |
| Mechanical ventilation, n (%) | 42 (6.2) | 6 (5.4) | 36 (6.4) | 0.675 |
| Non-invasive ventilation, n (%) | 207 (30.7) | 49 (43.8) | 158 (28.1) | <0.001 |
| Acute respiratory distress syndrome, n (%) | 99 (14.7) | 46 (41.1) | 53 (9.4) | <0.001 |
| Hospital length of stay (days), median [IQR] | 10 [6–16] | 11 [7–17] | 10 [5–16] | 0.189 |
| Myocardial injury, n (%) | 130 (19.3) | 49 (43.8) | 81 (14.4) | <0.001 |
| Cardiac troponin (ng/L), median [IQR] | 18 [8–40] | 42 [21–75] | 13 [6–27] | <0.001 |
Abbreviations: CCS: chronic coronary syndromes; IQR: interquartile range. Bold text indicates a statistically significant difference with a p-value <0.05.